title: [Results of catheter embolization of renal cell carcinoma].
abstract: OBJECTIVE
  We pointed out the value of catheter embolisation of kidney tumours.
  
  
  METHODS
  We treated 42 patients with kidney tumours. For peripheral embolisation we placed Histoacryl or Ethibloc into the kidney artery via a transfemoral catheter. 33 patients had haematuria. 8 patients were lost for follow up. 26 patients were treated by embolisation alone and 8 patients were treated before nephrectomy.
  
  
  RESULTS
  Haematuria was stopped in 98% and never reoccurred. The intraoperative blood-loss was 600 ml on average. 55% of patients treated by embolisation alone died within the first year. 51% of patients suffered from a slight postinfarction syndrome. One patient died of sepsis and one had pulmonary insufficiency due to AV shunt and pulmonary embolism.
  
  
  CONCLUSIONS
  Peripheral embolisation of kidney tumours can be used successfully and is minimal invasive, in case of haematuria and pain. The perioperative risk is reduced due to limited blood loss.
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000792:Angiography; D002292:Carcinoma, Renal Cell / Q000098:blood supply / Q000401:mortality / Q000628:therapy*; D003131:Combined Modality Therapy; D003973:Diatrizoate; D004338:Drug Combinations; D004621:Embolization, Therapeutic; D004659:Enbucrilate; D005227:Fatty Acids; D005260:Female; D005500:Follow-Up Studies; D006417:Hematuria / Q000000981:diagnostic imaging / Q000628:therapy; D006801:Humans; D007680:Kidney Neoplasms / Q000098:blood supply / Q000401:mortality / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D009392:Nephrectomy; D011409:Propylene Glycols; D012597:Sclerosing Solutions; D015996:Survival Rate; D015028:Zein
chemical_list: D004338:Drug Combinations; D005227:Fatty Acids; D011409:Propylene Glycols; D012597:Sclerosing Solutions; D003973:Diatrizoate; D015028:Zein; C020481:alcoholic prolamine solution; D004659:Enbucrilate
vernacular_title: Ergebnisse nach Katheterembolisation bei Nierenzellkarzinom.